[ad_1]
Abbott Laboratories (NYSE: ABT ) has contributed significantly to COVID treatment activities by providing test kits, and the healthcare conglomerate’s profits have benefited in recent years. Since the demand for coronavirus diagnostics has dropped significantly, the company has banked on a strong R&D pipeline, with various product launches lined up, to keep it going.
However, management’s cautious guidance – although the outlook is higher than pre-pandemic numbers – suggests the current weakness will continue this year.. Interestingly, the forecast for sales related to COVID tests is $750 million for the first quarter and about $2 billion for fiscal 2023. Meanwhile, the top line is expected to be affected by unfavorable exchange rates.
A good buy?
ABT has long been an investor favorite, thanks to regular dividend increases and a decent yield of about 2% above the benchmark S&P 500 average. Shares have fluctuated since peaking more than a year ago and currently trade just above $100. It is expected to double its growth in the next twelve months, creating significant shareholder value. The majority of experts following the stock recommend buying.
Going forward, Abbott’s diversified business model will be useful in meeting challenges like the fall in COVID diagnostics. In January, Navitor, the company’s next-generation transcatheter aortic valve implantation system, received FDA approval. Previously, the FreeStyle Libre 2 and FreeStyle Libre 3 integrated a continuous glucose monitoring system sensor for integration with the automatic insulin delivery system to achieve regulation.
Baby Formula Blues
Meanwhile, an investigation by the Department of Justice into an infant formula manufacturing facility in Michigan came as a setback for the company a few months ago. Earlier, the factory shut down and stopped production due to lack of sanitation. The company also began recalling popular infant formula like Similac, which led to a shortage of the product on the market.
From Abbott Laboratories’ Q4 2022 earnings conference call:
“When we remember the impact of the efforts of testing COVID over the past few years, it is clear that success in this area will have a positive impact on the company. It strengthens its strategic position in diagnostics through the expansion of the base of installed instruments, including ID NOW, the testing platform point-of-care molecular rapidly, and through the opening of new testing channels such as doctor’s office and home testing.”
Finance
The company is set to report financial results for the first three months of fiscal 2023 on April 19, in the morning. It enjoys the rare distinction of not missing the earnings forecast even once a month, and this trend is maintained in the fourth quarter. Although revenue declined twice to $10.1 billion in the December quarter, it exceeded forecasts. There were weaknesses in all operating segments and geographic divisions. At $1.03 per share, adjusted earnings were down 22%.
ABT opened Tuesday’s session at $104.42 and traded slightly higher in the early hours. It has lost about 5% since the beginning of the year.
[ad_2]
Source link